Clinical trials: Refractory to Standard Therapies
Pediatric Oncology
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Dose escalation phase of the study : To define the safety profile, maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of regorafenib administered orally as a single agent in a 3-weeks-on/1- week-off schedule in…
- Trial name
- NCT02085148
- Testing
- Regorafenib (BAY73-4506), Vincristine (Cellcristin®), Irinotecan (Irinotecan Cell pharm®)
- Where
- 12 sites in France, Italy and 2 more
- Volunteers
- 62 people
- Sponsor
- Bayer
Unspecified Adult Solid Tumor, Protocol Specific
GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as GDC-0449, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00607724
- Testing
- GDC-0449
- Volunteers
- 68 people
- Sponsor
- Genentech, Inc.
Relapsed/Refractory Large B-Cell Lymphoma
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
To evaluate the efficacy and safety of Linperlisib combined with standard immunochemotherapy in patients with R/R LBCL.
- Trial name
- NCT06489808
- Testing
- Linperlisib, Rituximab, Gemcitabine
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Tumors
One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy
This study will include a one time intravenous (IV) infusion of Clostridium novyi-NT (C. novyi-NT) spores to treat solid tumors which have not responded to standard therapy.
- Trial name
- NCT00358397
- Testing
- Clostridium novyi-NT spores
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cervical Cancer, Vaginal Cancer
Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00005941
- Testing
- therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.
Evaluate the safety, tolerability and the tolerated maximum dose of MEDI-575 in adult subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy exists.
- Trial name
- MEDI-575 (NCT00816400)
- Testing
- MEDI-575
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- MedImmune LLC
Gastric Cancer
TAS-102 and Anlotinib in ≥3 Lines mGC
To determine the efficacy and safety of TAS-102 and Anlotinib in patients with metastatic gastric cancer who had been treated with ≥ 2 lines of prior standard chemotherapy
- Trial name
- NCT05029102
- Testing
- TAS 102, Anlotinib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Zhejiang University
Colorectal Cancer
A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC）
A Phase II study on dose optimization of fruquintinib in elderly metastatic colorectal cancer patients refractory to standard treatment.
- Trial name
- DOFEMCRC (NCT05025631)
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Zhen-Yu Ding
Aplastic Anemia
A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard Treatment
This research study is testing a medicine called avatrombopag in adults with aplastic anemia, a rare condition where the bone marrow does not produce enough blood cells.
- Trial name
- NCT07786922
- Testing
- Avatrombopag 20 mg Oral Tablet
- Volunteers
- 26 people
- Sponsor
- Swedish Orphan Biovitrum
Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body…
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma
- Trial name
- NCT04579224
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 448 sites in United States
- Volunteers
- 131 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of YYB101, HGF-neutralizing humanized Mab, in advanced solid tumors patients who are refractory to standard…
- Trial name
- NCT02499224
- Testing
- YYB101
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- CellabMED
Heart Decompensation
Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure
Open label study of levosimendan; planned comparison for effectiveness and safety to historic matched case controls from participating sites.
- Trial name
- NCT02973620
- Testing
- Levosimendan
- Sponsor
- Tenax Therapeutics, Inc.
Pancreatic Neoplasms
Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies
This study is a Phase I/II study. In Phase I of this study, the objective is to determine the maximum tolerated dose (MTD) of combination therapy with Aroplatin and gemcitabine (Gemzar®) in subjects with unresectable, locally…
- Trial name
- NCT00081549
- Testing
- Aroplatin (Liposomal NDDP, L-NDDP)
- Volunteers
- 111 people
- Sponsor
- Aronex Pharmaceuticals
Solid Tumor
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
An open label, dose escalation and dose expansion study to evaluate the safety, tolerability, and anti-tumor activity of STP707 with IV administration in subjects with advanced/metastatic or surgically unresectable solid tumors…
- Trial name
- NCT05037149
- Testing
- STP707
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Sirnaomics
Diabetic Foot Ulcer
Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone
This randomized controlled study evaluates the adjuvant use of Derm-Maxx in patients with diabetic foot ulcers
- Trial name
- NCT06455475
- Testing
- Derm-Maxx
- Where
- 11 sites in United States
- Volunteers
- 120 people
- Sponsor
- Capsicure, LLC
Aspergillosis
MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)
Invasive aspergillosis is a type of fungal infection typically identified in very sick patients (for example, patients with cancer or who have had a bone marrow or organ transplant).
- Trial name
- NCT00076869
- Testing
- MK0991, caspofungin acetate, Comparator: amphotericin B, Comparator: lipid formulation of amphotericin B and/or azole
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myelogenous Leukemia
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
This Phase 1b study will determine the maximum tolerated dose of KX2-391 given as a once-daily dose, in elderly patients with acute myelogenous leukemia.
- Trial name
- NCT01397799
- Testing
- KX2-391
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Kinex Pharmaceuticals Inc.
Eosinophilic Granulomatosis With Polyangiitis
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
- Trial name
- OCEAN (NCT05263934)
- Testing
- Depemokimab, Mepolizumab
- Where
- 63 sites in United States, Argentina and 16 more
- Volunteers
- 163 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies
This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again…
- Trial name
- NCT06592222
- Testing
- Elranatamab, Standard of care
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Pancreatic Cancer
Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer
This is a dose-seeking study that will test the safety of increasing doses of Rexin-G, given intravenously, in patients with advanced or metastatic pancreatic cancer who have failed standard chemotherapy.
- Trial name
- NCT00121745
- Testing
- Rexin-G Dose 1, Rexin-G Dose 2, Rexin-G Dose 3
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Epeius Biotechnologies